• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Low Rate of Intrathecal Baclofen Pump Catheter ‐Related Complications: Long‐Term Study in Over 100 Adult Patients Associated With Reinforced Catheter
ConclusionsReported CRCs have been high for ITB pump systems. Ours is the first large cohort, long ‐term study of CRCs related to reinforced catheters; additionally, our low CRC rate compares favorably to previously published data. Thus, implantation of reinforced catheters may be associated with a low CRC rate.
Source: Neuromodulation: Technology at the Neural Interface - May 11, 2021 Category: Biotechnology Authors: Christina N. Feller, Ahmed J. Awad, Mary Elizabeth S. Nelson, Nicholas Ketchum, Peter A. Pahapill Tags: Clinical Research Source Type: research

A single, clinically relevant dose of the GABAB agonist baclofen impairs visuomotor learning.
This article is protected by copyright. All rights reserved. PMID: 33085094 [PubMed - as supplied by publisher]
Source: The Journal of Physiology - October 21, 2020 Category: Physiology Authors: Johnstone A, Grigoras I, Petitet P, Capitão LP, Stagg CJ Tags: J Physiol Source Type: research

Intrathecal Baclofen Infusion Pumps in the Treatment of Spasticity: A Retrospective Cohort Study in a Portuguese Centre.
CONCLUSION: Intrathecal baclofen infusion pumps are safe and effective in the treatment of spasticity. Infusion pumps provide a high level of satisfaction regarding treatment and quality of life. PMID: 31851884 [PubMed - in process]
Source: Acta Medica Portuguesa - December 19, 2019 Category: General Medicine Tags: Acta Med Port Source Type: research

Intrathecal baclofen as a treatment for spasticity: Review of the cases treated in our hospital.
CONCLUSIONS: Intrathecal baclofen is a simple technique with good results for improving the quality of life of patients with spasticity. PMID: 31208871 [PubMed - as supplied by publisher]
Source: Neurocirugia - June 13, 2019 Category: Neurosurgery Authors: Santin-Amo JM, Flores-Justa A, Román-Pena P, Raposo-Furelos M, Frieiro-Dantas C, Serramito García R, Villa JM, Gelabert-González M Tags: Neurocirugia (Astur) Source Type: research

New Partnership Forms to Develop Breakthrough Neuromodulation Device
WeHealth, an e-health department of Servier Group, said it is in a partnership with Pathmaker Neurosystems, a pioneering clinical-stage bioelectronic medicine company. The two companies revealed plans to develop and commercialize the first neuromodulation technology designed to treat muscle spasticity non-invasively. The new technology will be known as the MyoRegulator device. The new MyoRegulator PM-200 provides a non-invasive treatment option for patients suffering from muscle spasticity, a common condition found in many patients suffering from stroke, cerebral palsy, multiple sclerosis, spinal cord injury, and traumatic...
Source: MDDI - March 26, 2019 Category: Medical Devices Authors: Kristopher Sturgis Tags: Business Source Type: news

Rectal administration of baclofen at the end of life
Spasticity can be a complicating symptom of a variety of neurological conditions such as multiple sclerosis, motor neuron disease, Creutzfeldt-Jakob disease, or post-stroke. Several pharmacological treatment options are available, including baclofen, tizanidine, gabapentin, botulinum toxin A and tetrahydrocannabinol/canabidiol (1, 2). However, treatment feasibility decreases as the end of life approaches, e.g. when patients are no longer able to tolerate oral medications, the onset of action would be too long, or the initiation of parenteral drug therapy (intravenous, intrathecal) is no longer indicated or appropriate.
Source: Journal of Pain and Symptom Management - August 7, 2018 Category: Palliative Care Authors: Charlotte Selge, Claudia Bausewein, Constanze Remi Source Type: research

Intrathecal Versus Oral Baclofen: A Matched Cohort Study of Spasticity, Pain, Sleep, Fatigue, and Quality of Life
Conclusions Long-term treatment with intrathecal compared with oral baclofen is associated with reduced spasm frequency and severity as well as greater dose stability. These benefits must be weighed against the risks of internal pump and catheter placement in patients considering intrathecal baclofen therapy.
Source: PMandR - November 22, 2015 Category: Rehabilitation Source Type: research

Intrathecal versus Oral Baclofen; a Matched Cohort Study of Spasticity, Pain, Sleep, Fatigue and Quality of Life
Conclusions Long-term treatment with intrathecal compared to oral baclofen is associated with reduced spasm frequency and severity as well as greater dose stability. These benefits must be weighted against the risks of internal pump and catheter placement in patients considering intrathecal baclofen therapy.
Source: PMandR - October 21, 2015 Category: Rehabilitation Source Type: research

Intrathecal Baclofen Dosing Regimens: A Retrospective Chart Review
ConclusionSignificant differences in dosing were found between diagnoses and trended to differ by ambulatory status at the end of the study, and similar trends could be observed in achieving initial stable dose.
Source: Neuromodulation: Technology at the Neural Interface - October 1, 2015 Category: Biotechnology Authors: Jacob S. Clearfield, Mary Elizabeth S. Nelson, John McGuire, Lisa E. Rein, Sergey Tarima Tags: Clinical Research Source Type: research

Drugs used to treat joint and muscle disease
Publication date: Available online 19 February 2015 Source:Anaesthesia & Intensive Care Medicine Author(s): David G. Lambert Joint disease: Arthritis can be simply broken into osteoarthritis and rheumatoid arthritis (RA). Osteoarthritis is treated with symptomatic pain relief and surgery. RA is a chronic autoimmune disease that causes inflammation of joints (leading to their destruction), tissues around joints and other organ systems. Treatment (for pain) of RA in the first instance is with non-steroidal anti-inflammatory drugs, with second-line treatment using disease-modifying antirheumatic drugs (DMARDs). DMAR...
Source: Anaesthesia and intensive care medicine - February 24, 2015 Category: Anesthesiology Source Type: research

Subcutaneous Use of Baclofen
Painful spasticity is an often debilitating symptom that occurs mostly in patients with neurologic diseases such as multiple sclerosis or stroke. Treatment approaches include pharmacologic and nonpharmacologic interventions. Baclofen is one of the drugs commonly used to decrease elevated muscle tone. This GABAB agonist acts primarily by limiting the release of excitatory neurotransmitters on the spinal level, thereby decreasing spastic muscle tone. Baclofen is licensed for oral and intrathecal use in spasticity. The abrupt cessation of baclofen therapy can lead to withdrawal syndromes including epileptic seizures. Here, we...
Source: Journal of Pain and Symptom Management - May 30, 2014 Category: Palliative Care Authors: Constanze Rémi, Elisabeth Albrecht Tags: Letters Source Type: research

Adherence Associated With Oral Medications in the Treatment of Spasticity
Objective: To examine adherence to baclofen, tizanidine, and dantrolene (U.S. Food and Drug Administration–approved oral spasticity medications), and identified determinants of adherence.Design: A retrospective administrative claims data analysis that used medical and pharmacy claims data and enrollment information from a large, national U.S. health plan.Subjects and Methods: The subjects were commercial health plan members who initiated treatment on baclofen, tizanidine, or dantrolene from January 1, 2004, through September 30, 2009, and who had stroke, spinal cord injury, traumatic brain injury, cerebral palsy, or mult...
Source: PM and R - May 6, 2013 Category: Rehabilitation Authors: Rachel Halpern, Patrick Gillard, Glenn D. Graham, Sepideh F. Varon, Richard D. Zorowitz Tags: Original Research Source Type: research